Does local drug delivery still hold therapeutic promise for brain cancer? A systematic review

Bastiancich, C., Bozzato, E., Henley, I. and Newland, B. ORCID: https://orcid.org/0000-0002-5214-2604 2021. Does local drug delivery still hold therapeutic promise for brain cancer? A systematic review. Journal of Controlled Release 337 , pp. 296-305. 10.1016/j.jconrel.2021.07.031

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (729kB)

Abstract

Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Despite the gold standard treatment combining surgical resection, radiation and adjuvant plus concomitant chemotherapy with the alkylating agent temozolomide (TMZ), the prognosis remains poor (5-year survival rate < 10%). Over the last three decades, a vast array of drug delivery systems (DDS) have been developed for the local treatment of GBM, with the majority of the characterization being undertaken in pre-clinical models. We aimed to gain an overview of the potential efficacy of such local delivery systems in comparison to the systemic drug administration. Methods In this paper, a systematic search of Pubmed, Web of Science, and Scopus was performed using pre-determined search terms. Studies were assessed for eligibility based on specific inclusion and exclusion criteria. A total of fifteen publications were included for analysis of local vs systemic group median survival, tumor volume and adverse events, with five brought forward for a meta-analysis. Results The majority of studies showed local delivery to be more efficacious than systemic administration, regardless of the drug, animal model, type of DDS used, or duration of the study. The meta-analysis also showed that the mean difference between median survival ratios was statistically significantly in favor of local delivery. Conclusion Preclinical evidence shows that there is a firm rationale for further developing DDS for local therapeutic delivery to GBM and other brain cancers.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Publisher:	Elsevier
ISSN:	0168-3659
Date of First Compliant Deposit:	23 August 2021
Date of Acceptance:	17 July 2021
Last Modified:	29 Sep 2024 05:00
URI:	https://orca.cardiff.ac.uk/id/eprint/143585

Citation Data

Cited 24 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item